Drug Profile
Itacitinib - Incyte Corporation
Alternative Names: IBI-377; INCB-039110; INCB-039110-adipate; INCB-39110; Itacitinib-adipateLatest Information Update: 17 Jan 2024
Price :
$50
*
At a glance
- Originator Incyte Corporation
- Developer ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP); AstraZeneca; H. Lee Moffitt Cancer Center and Research Institute; Incyte Corporation; Innovent Biologics; National Cancer Institute (USA); University of Utah
- Class Acetonitriles; Anti-inflammatories; Antianaemics; Antibronchitics; Antineoplastics; Antipsoriatics; Antirheumatics; Azetidines; Fluorocarbons; Piperidines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
- Mechanism of Action Janus kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cytokine release syndrome; Diffuse large B cell lymphoma; Diffuse scleroderma; Haematological malignancies; Haemophagocytic lymphohistiocytosis; Hodgkin's disease; Immunological disorders; Myelofibrosis; Non-small cell lung cancer; Solid tumours
- Phase I/II Bronchiolitis obliterans; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
- Phase I Graft-versus-host disease; T-cell prolymphocytic leukaemia
- No development reported Aplastic anaemia; Liver cancer; Malignant melanoma; Soft tissue sarcoma
- Discontinued Pancreatic cancer; Plaque psoriasis; Rheumatoid arthritis
Most Recent Events
- 09 Dec 2023 Updated adverse events data from the phase II trial for Cytokine release syndrome presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 03 Nov 2023 Incyte Corporation terminates the phase-III GRAVITAS-309 trial in Graft-versus-host disease (Combination therapy, Treatment-naïve) in Austria, Belgium, Canada, Czech Republic, Denmark, England, Finland, France, Germany, Greece, Hungary, Israel, Italy, Poland, Spain, Sweden, Switzerland, UK and USA, due to insufficient efficacy to support moving into Part 2 of the study (PO) (NCT03584516),
- 13 Oct 2023 Incyte Corporation terminates a phase I/II trial in Bronchiolitis Obliterans in Belgium, Canada, USA citing a strategic business decision(PO) (EudraCT2019-004171-39) (NCT03978637)